{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:43:12Z","timestamp":1781246592767,"version":"3.54.1"},"reference-count":42,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The purpose of this publication is to summarize the results of the vaginal erbium:yttrium-aluminum-garnet (Er:YAG) Smooth\n                    <jats:sup>\u00ae<\/jats:sup>\n                    laser (VEL) on the vaginal atrophy component of the genitourinary syndrome of menopause (GSM). GSM has two categories of clinical signs related to estrogen deficiency: symptoms of vulvovaginal atrophy (VVA) and urinary symptoms. This symptomatology is chronic, progressive over the years and affects a majority of women concerned by natural menopause but not exclusively: we must also consider the growing number of survivors of gynecological or non-gynecological cancers (breast, cervix, uterus, vagina, anus, etc.). At a time when hormonal treatment of menopause is contested as is the installation of under urethra prosthesis, the innovation provided by the VEL technology has the merit of offering the women concerned an effective therapeutic alternative with the security of a patent. The VEL technology has an original and unique process: acting only by thermal effect and not by ablation on tissue, VEL is a safe solution in terms of side effects and potential complications. Studies have been increasing since 2012 and all demonstrate a significant improvement in the GSM signs and symptoms, as well as an improved sexual life after VEL treatment. Double-blind, placebo-controlled, randomized studies are expected in order to ultimately confirm the safety and effectiveness of VEL.\n                  <\/jats:p>","DOI":"10.1515\/hmbci-2019-0024","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T04:34:31Z","timestamp":1576730071000},"source":"Crossref","is-referenced-by-count":10,"title":["Genitourinary syndrome of menopause (GSM) and laser VEL: a review"],"prefix":"10.1515","volume":"41","author":[{"given":"David","family":"Elia","sequence":"first","affiliation":[{"name":"Vela-France (Vaginal Erbium Laser Academy France) , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gambacciani","sequence":"additional","affiliation":[{"name":"Vela-Italia (Vaginal Erbium Laser Academy Italia) , Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Berreni","sequence":"additional","affiliation":[{"name":"Vela-France (Vaginal Erbium Laser Academy France) , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marc","family":"Bohbot","sequence":"additional","affiliation":[{"name":"Vela-France (Vaginal Erbium Laser Academy France) , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Druckmann","sequence":"additional","affiliation":[{"name":"Vela-France (Vaginal Erbium Laser Academy France) , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Geoffrion","sequence":"additional","affiliation":[{"name":"Vela-France (Vaginal Erbium Laser Academy France) , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Haab","sequence":"additional","affiliation":[{"name":"Vela-France (Vaginal Erbium Laser Academy France) , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niko","family":"Heiss","sequence":"additional","affiliation":[{"name":"Vela-France (Vaginal Erbium Laser Academy France) , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Rygaloff","sequence":"additional","affiliation":[{"name":"Vela-France (Vaginal Erbium Laser Academy France) , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Russo","sequence":"additional","affiliation":[{"name":"Vela-Italia (Vaginal Erbium Laser Academy Italia) , Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"key":"2025121207194632984_j_hmbci-2019-0024_ref_001_w2aab3b7c83b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and the North American Menopause Society. Menopause. 2014;21:1063\u20138.","DOI":"10.1097\/GME.0000000000000329"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_002_w2aab3b7c83b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6:2133\u201342.","DOI":"10.1111\/j.1743-6109.2009.01335.x"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_003_w2aab3b7c83b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"b-Levine K, Williams R, Hartmann K. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active post-menopausal women. Menopause. 2008;15:661\u20136.","DOI":"10.1097\/gme.0b013e31815a5168"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_004_w2aab3b7c83b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Palma F, Volpe A, Villa P, Cagnacci A. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas. 2016;83:40\u20134.","DOI":"10.1016\/j.maturitas.2015.09.001"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_005_w2aab3b7c83b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Shifren JL. Genitourinary syndrome of menopause. Clin Obstet Gynecol. 2018;61:508\u201316.","DOI":"10.1097\/GRF.0000000000000380"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_006_w2aab3b7c83b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Ogrinc UB, Sen\u010dar S, Lenasi H. Novel minimally invasive laser treatment of urinary incontinence in women. Lasers Surg Med. 2015;47:689\u201397.","DOI":"10.1002\/lsm.22416"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_007_w2aab3b7c83b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Willhite LA, O\u2019Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy. 2001;21:464\u201380.","DOI":"10.1592\/phco.21.5.464.34486"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_008_w2aab3b7c83b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Quinn SD, Domoney C. The effects of hormones on urinary incontinence in postmenopausal women. Climacteric. 2009;12:106\u201313.","DOI":"10.1080\/13697130802630083"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_009_w2aab3b7c83b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;10:CD001405.","DOI":"10.1002\/14651858.CD001405.pub3"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_010_w2aab3b7c83b1b6b1ab2b1c10Aa","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results for the Women\u2019s Health Initiative. Randomized control trial. J Am Med Assoc. 2002;228:321\u20133."},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_011_w2aab3b7c83b1b6b1ab2b1c11Aa","unstructured":"HAS. Commission de la transparence. R\u00e9\u00e9valuation des traitements hormonaux de la m\u00e9nopause. Rapport d\u2019\u00e9valuation.  2014 : 1\u2013 91."},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_012_w2aab3b7c83b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Crawford SL, Crandall C, Derby CA, El Khoudary SR, Waetjen LE, Fischer M, et al. Menopausal hormone therapy trends before versus after 2002: impact of the Women\u2019s Health Initiative Study Results. Menopause. 2018;26:588\u201397.","DOI":"10.1097\/GME.0000000000001282"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_013_w2aab3b7c83b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Peng Q, Juzeniene A, Chen J, Svaasand LO, Warloe T, Giercksky KE, et al. Lasers in medicine. Rep Prog Phys. 2008;71:056701.","DOI":"10.1088\/0034-4885\/71\/5\/056701"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_014_w2aab3b7c83b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Vicariotto F, De Seta F, Faoro V, Raichi M. Dynamic quadripolar radiofrequency treatment of vaginal laxity\/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety. Minerva Ginecol. 2017;69:342\u20139.","DOI":"10.23736\/S0026-4784.17.04072-2"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_015_w2aab3b7c83b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"El-Domyati M, Abd-El-Raheem T, Medhat W, Abdel-Wahab H, Anwer MA. Multiple fractional erbium: yttrium-aluminum-garnet laser sessions for upper facial rejuvenation: clinical and histological implications and expectations. J Cosmet Dermatol. 2014;13:30\u20137.","DOI":"10.1111\/jocd.12079"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_016_w2aab3b7c83b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Abrahamse H. Regenerative medicine, stem cells, and low-level laser therapy: future directives. Photomed Laser Surg. 2012;30:681\u20132.","DOI":"10.1089\/pho.2012.9881"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_017_w2aab3b7c83b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Gambacciani M, Levancini M, Russo E, Vacca L, Simoncini T, Cervigni M. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric. 2018;21:148\u201352.","DOI":"10.1080\/13697137.2018.1436538"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_018_w2aab3b7c83b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Gaspar A, Brandi H, Gomez V, Luque D. Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med. 2016;49:160\u20138.","DOI":"10.1002\/lsm.22569"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_019_w2aab3b7c83b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17:363\u20139.","DOI":"10.3109\/13697137.2014.899347"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_020_w2aab3b7c83b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Sokol ER, Karram MM. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause. 2016;23:1102\u20137.","DOI":"10.1097\/GME.0000000000000700"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_021_w2aab3b7c83b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191\u2013208.","DOI":"10.1080\/009262300278597"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_022_w2aab3b7c83b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Corcos J, Beaulieu S, Donovan J, Naughton M, Gotoh M. Symptom Quality of Life Assessment Committee of the First International Consultation on Incontinence. Quality of life assessment in men and women with urinary incontinence. J Urol. 2002;168:896\u2013905.","DOI":"10.1016\/S0022-5347(05)64540-5"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_023_w2aab3b7c83b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas. 1995;Suppl. 1:S1\u20135.","DOI":"10.1016\/0378-5122(95)00956-6"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_024_w2aab3b7c83b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Gandhi J, Chen A, Dagur G, Schwamb R, Weissbart SJ, Khan SA. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, aetiology, evaluation and management. Am J Obstet Gynecol. 2016;215:704\u201311.","DOI":"10.1016\/j.ajog.2016.07.045"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_025_w2aab3b7c83b1b6b1ab2b1c25Aa","unstructured":"Vizintin Z, Mario Rivera M, Fistoni\u0107 I, Sara\u00e7o\u011flu F, Guimares P, Gaviria J, et al. Novel minimally invasive VSP Er:YAG laser treatments in gynecology. J LAHA. 2012;2012:46\u201358."},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_026_w2aab3b7c83b1b6b1ab2b1c26Aa","unstructured":"Fistonic I, Findri-Gustek S, Fistonic N. Minimally invasive laser procedure for early stages of stress urinary incontinence (SUI). J LAHA. 2012;2012:67\u201374."},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_027_w2aab3b7c83b1b6b1ab2b1c27Aa","unstructured":"Gaspar A. Comparaison du nouveau traitement au laser mini-invasif Er: YAG et du traitement hormonal substitutif dans le traitement de l\u2019atrophie vaginale. Climacteric. 2014;17(Suppl 1):48\u2013108, 124."},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_028_w2aab3b7c83b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Gambacciani M, Levancini M, Cervigni M. Vaginal erbium laser for genitourinary syndrome of menopause Climacteric. 2015;18:1\u20137.","DOI":"10.3109\/13697137.2015.1071608"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_029_w2aab3b7c83b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Gambacciani M, Levancini M. Vaginal erbium laser as second generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause. 2017;24(3):316\u2013319.","DOI":"10.1097\/GME.0000000000000761"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_030_w2aab3b7c83b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Gambacciani M, Torelli MG, Martella L, Bracco GL, Casagrande AG, Albertin E, et al. Rationale and design for the Vaginal Erbium Laser Academy Study (VELAS): an international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence. Climacteric. 2015;18(Suppl 1):43\u20138.","DOI":"10.3109\/13697137.2015.1071608"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_031_w2aab3b7c83b1b6b1ab2b1c31Aa","unstructured":"Bojanini JF, Mej\u00eda AM. Laser treatment of vaginal atrophy in post-menoause and post-gynecological cancer patients. J LAHA. 2014;1:65\u201371."},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_032_w2aab3b7c83b1b6b1ab2b1c32Aa","unstructured":"Bojanini JF. Treatment of Genitourinary syndrome of menopause with Erbium:YAG laser: a prospective study of efficacy and safety of the treatment for women after menopause of natural origin and therapy-induced menopause in breast cancer survivors. J LAHA. 2016;1:35\u201340."},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_033_w2aab3b7c83b1b6b1ab2b1c33Aa","unstructured":"Barber MA, Idoya E. Patient satisfaction with vaginal erbium laser treatment of stress urinary incontinence, vaginal relaxation syndrome and genito-urinary syndrome of menopause. J LAHA. 2016.www.laserandhealth.com."},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_034_w2aab3b7c83b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Lin YH, Hsieh WC, Huang L, Liang CC. Effect of non-ablative laser treatment on overactive bladder symptoms, urinary incontinence and sexual function in women with urodynamic stress incontinence. Taiwan J Obstet Gynecol. 2017;56:815\u201320.","DOI":"10.1016\/j.tjog.2017.10.020"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_035_w2aab3b7c83b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Gaspar A, Maestri S, Silva J, Brandi H, Luque D, Koron N, et al. Intraurethral Erbium:YAG laser for the management of urinary symptoms of genitourinary syndrome of menopause: a pilot study. Lasers Surg Med. 2018;50(8):802\u20137.","DOI":"10.1002\/lsm.22826"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_036_w2aab3b7c83b1b6b1ab2b1c36Aa","unstructured":"FDA Warns Against Use of Energy-Based Devices to Perform Vaginal \u2018Rejuvenation\u2019 or Vaginal Cosmetic Procedures: FDA Safety Communication. 2018 ."},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_037_w2aab3b7c83b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Gambacciani M, Cervigni M. FDA\u2019s Warns Against Use of Energy-Based Devices: The VELA\u00ae Safety Communication. Biomed J Sci Tech Res. 2018;12:9102\u20139104.","DOI":"10.26717\/BJSTR.2018.12.002224"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_038_w2aab3b7c83b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Tadir Y, Gaspar A, Lev-Sagie A, Alexiades M, Alinsod R, Bader A, et al. Light and energy-based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med. 2017;49:137\u201359.","DOI":"10.1002\/lsm.22637"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_039_w2aab3b7c83b1b6b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"Gambacciani M, Palacios S. Laser therapy for the restoration of vaginal function. Maturities. 2017;99:10\u201315.","DOI":"10.1016\/j.maturitas.2017.01.012"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_040_w2aab3b7c83b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"Gambacciani M, Cervigni M. Erbium laser in gynaecology: aims, aspirations and action points. Climacteric. 2015;18:2\u20133.","DOI":"10.3109\/13697137.2015.1082258"},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_041_w2aab3b7c83b1b6b1ab2b1c41Aa","unstructured":"The American College of Obstetricians and Gynaecologists. Fractional Laser Treatment of Vulvovaginal Atrophy Clearance: Position Statement. 2016."},{"key":"2025121207194632984_j_hmbci-2019-0024_ref_042_w2aab3b7c83b1b6b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"Blaganje M, \u0160\u0107epanovi\u0107 D, \u017dgur L, Verdenik I, Pajk F, Lukanovi\u0107 A. Not ablative Er: YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2018;224:153\u20138.","DOI":"10.1016\/j.ejogrb.2018.03.038"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/hmbci.ahead-of-print\/hmbci-2019-0024\/hmbci-2019-0024.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0024\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0024\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:10:47Z","timestamp":1765527047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0024\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,19]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,14]]},"published-print":{"date-parts":[[2020,3,26]]}},"alternative-id":["10.1515\/hmbci-2019-0024"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2019-0024","relation":{},"ISSN":["1868-1891"],"issn-type":[{"value":"1868-1891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,19]]},"article-number":"20190024"}}